Di­anthus marks Nas­daq de­but with PhI hit; Ar­bu­tus shuts oral RNA and coro­n­avirus pro­grams

As Di­anthus Ther­a­peu­tics starts trad­ing on Nas­daq, it’s al­so mark­ing an­oth­er mile­stone with pos­i­tive Phase I safe­ty and phar­ma­co­ki­net­ic da­ta.

DNTH103, a se­lec­tive in­hibitor of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER